Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 5/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239049 | 1.00 | KLK7 (0.41) | KLK7GAATHRBSMN1; SMN2REN | |
| SCHEMBL3239051 | 1.00 | KLK7 (0.41) | KLK7GAATHRBSMN1; SMN2REN | |
| SCHEMBL3237190 | 0.88 | BACE1 (0.42) | KLK7RENKLK5 | |
| SCHEMBL3237197 | 0.88 | BACE1 (0.42) | KLK7RENKLK5 | |
| SCHEMBL3237186 | 0.88 | BACE1 (0.42) | KLK7RENKLK5 | |
| SCHEMBL3236557 | 0.88 | BACE1 (0.40) | KLK7EPHX1MAPTNPSR1 | |
| SCHEMBL3236565 | 0.88 | BACE1 (0.40) | KLK7EPHX1MAPTNPSR1 | |
| SCHEMBL3236574 | 0.88 | BACE1 (0.40) | KLK7EPHX1MAPTNPSR1 | |
| SCHEMBL3230915 | 0.88 | KLK7 (0.38) | KLK7GAATHRBSMN1; SMN2REN | |
| SCHEMBL3230913 | 0.88 | KLK7 (0.38) | KLK7GAATHRBSMN1; SMN2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | KLK7 1466/4885GAA 27/4885THRB 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.